VistaGen Therapeutics received a notice from the US Patent and Trademark Office regarding the certain methods of production for AV-101.
VistaGen Therapeutics (NASDAQ:VTGN) received a notice from the US Patent and Trademark Office regarding the certain methods of production for AV-101.
As quoted in the press release:
“We are pleased that the USPTO has allowed this U.S. patent relating to production methods for AV-101 at this significant period in its clinical development. Together with other granted patents and pending patent applications, this new patent will enhance our exclusivity for AV-101,” stated Shawn Singh, Chief Executive Officer of VistaGen. “We are also pleased that a corresponding patent application has been granted in China. Together with the Notice of Intention to Grant European Patent 2948140B1, which relates to treatment of depression with AV-101 and its use to reduce levodopa-induced dyskinesia associated with Parkinson’s disease therapy, this Notice of Allowance in the U.S. is yet another important step forward, further strengthening and expanding our AV-101 IP portfolio.”